Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
4 clinical trials · Condition
◉ Watch Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751) | National Cancer Institute (NCI) | 2025-10-31 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT05920798) | Mayo Clinic | 2023-09-28 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589) | National Cancer Institute (NCI) | 2022-06-30 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
Track Recurrent Fallopian Tube High Grade Serous Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.